PhRMA

PhRMA Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from PhRMA, Medical and health, 670 Maine Avenue SW Ste. 1000, Washington D.C., DC.

We represent America’s innovative biopharmaceutical research & biotechnology companies, advocating for policies that support the discovery of new medicines and ensure broad patient access to safe, effective treatments.

Vaccines are built with decades of knowledge, and every vaccine is carefully designed for safety and protection.America ...
05/11/2026

Vaccines are built with decades of knowledge, and every vaccine is carefully designed for safety and protection.

America has addressed the threat of diseases like smallpox, polio, and hepatitis B, but that progress isn’t permanent. When vaccination rates fall, these deadly diseases return.

Get the facts about vaccines here: https://ow.ly/hTre50YXAkK

MFN price controls don’t just threaten America’s leadership in the biopharmaceutical industry. The ripple effects would ...
05/09/2026

MFN price controls don’t just threaten America’s leadership in the biopharmaceutical industry. The ripple effects would cost American jobs, stunt economic growth and jeopardize the retirement savings of American workers.

The stakes are too high to ignore. We must protect our Americans, their livelihood and our economic future.

05/08/2026

NEW INVESTMENT: Lilly pledged $4.5 billion in Indiana manufacturing, including its first dedicated genetic medicine facility. This commitment reflects the continued strength of America’s biopharmaceutical ecosystem and the importance of policies that support U.S. innovation and manufacturing.

Investments like these help drive medical progress, strengthen domestic supply chains and support high-quality jobs across the country.

This week, PhRMA convened researchers and scientists in Albany to meet with New York policymakers and share insights dra...
05/07/2026

This week, PhRMA convened researchers and scientists in Albany to meet with New York policymakers and share insights drawn from their work across the biopharmaceutical innovation pipeline — from drug discovery through development.

Representatives from eight companies took part in meetings, helping policymakers better understand the complexity of medical research and the real-world considerations that shape scientific progress for patients.

Learn more about the biopharmaceutical industry’s economic impact in New York and across the country: https://ow.ly/6LP150YW3h2

05/06/2026

Today, we launched a new campaign to shed light on how the 340B program is a goldmine for big nonprofit 340B hospitals.

These hospitals are getting billions of dollars from 340B medicine markups with no requirement that patients benefit. Because there are no clear rules or transparency requirements, hospitals can spend on luxury perks while patients face higher bills at the pharmacy counter.

That’s not what the 340B program was designed to do.

Patients deserve accountability and transparency. Washington needs to fix 340B.

https://ow.ly/QBm150YVwYI

05/05/2026

Maintaining U.S. leadership in life sciences requires action.

Our CEO, Stephen J. Ubl, joined CNBC to talk about what action is needed:

🧪 More efficient clinical trials
🚧 Fewer barriers from PBMs and insurers
🧬 Policies that support investment in innovation

The decisions we make today will determine whether America continues to lead.

The Washington Post Editorial Board is the latest to join the chorus of voices calling for federal reform of the 340B Pr...
05/04/2026

The Washington Post Editorial Board is the latest to join the chorus of voices calling for federal reform of the 340B Program.

The Board warns that unchecked growth has turned 340B into a profit center for large hospital systems, driving up costs for everyone else.

A few things to know:

1️⃣ 340B does not operate as a targeted safety net program.

2️⃣ Hospitals can pocket drug discounts without helping patients.

3️⃣ The program is driving higher costs for patients, employers and taxpayers.

4️⃣ Transparency and accountability are sorely lacking.

Read more:

MFN would weaken innovation, siphon billions from R&D and lead to hundreds of fewer lifesaving treatments and cures. Thi...
05/02/2026

MFN would weaken innovation, siphon billions from R&D and lead to hundreds of fewer lifesaving treatments and cures.

This hurts patients, especially the patients and their families who are waiting on cures for life-threatening or rare diseases.

Policymakers must reject MFN and protect cures for American patients.

05/01/2026

The future of medicine is expanding fast.

Scientists may soon be able to discover cures 10 or even 100 times faster than they can today.

04/30/2026

Patients care about getting the medicines they need.

But where those medicines are developed matters.

U.S. leadership means faster access for patients, high-value jobs and stronger national and economic security.

We can’t afford to fall behind.

Address

670 Maine Avenue SW Ste. 1000
Washington D.C., DC
20024

Telephone

+12028353400

Website

Alerts

Be the first to know and let us send you an email when PhRMA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to PhRMA:

Shortcuts

Share

Category